192 related articles for article (PubMed ID: 28553081)
1. Ten years of biosimilar recombinant human growth hormone in Europe.
Saenger P
Drug Des Devel Ther; 2017; 11():1505-1507. PubMed ID: 28553081
[TBL] [Abstract][Full Text] [Related]
2. Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data.
López-Siguero JP; Pfäffle R; Chanson P; Szalecki M; Höbel N; Zabransky M
Drug Des Devel Ther; 2017; 11():1489-1495. PubMed ID: 28553079
[TBL] [Abstract][Full Text] [Related]
3. Ten years of clinical experience with biosimilar human growth hormone: a review of safety data.
Borrás Pérez MV; Kriström B; Romer T; Walczak M; Höbel N; Zabransky M
Drug Des Devel Ther; 2017; 11():1497-1503. PubMed ID: 28553080
[TBL] [Abstract][Full Text] [Related]
4. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
Schiestl M; Zabransky M; Sörgel F
Drug Des Devel Ther; 2017; 11():1509-1515. PubMed ID: 28553082
[TBL] [Abstract][Full Text] [Related]
5. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
Pfäffle R; Bidlingmaier M; Kreitschmann-Andermahr I; Land C; Partsch CJ; Schwab KO; Sommer H; Backeljauw P; Kanumakala S; Loche S; Zouater H; Strasburger CJ
Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319
[TBL] [Abstract][Full Text] [Related]
6. Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study.
Loche S; Kanumakala S; Backeljauw P; Schwab KO; Lechuga-Sancho AM; Esmael A; Urosevic D; Boldea A; Zabransky M
Drug Des Devel Ther; 2024; 18():667-684. PubMed ID: 38454934
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: controversies as illustrated by rhGH.
Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
[TBL] [Abstract][Full Text] [Related]
8. Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies.
Lundberg E; Kriström B; Zouater H; Deleskog A; Höybye C
BMC Endocr Disord; 2020 Apr; 20(1):55. PubMed ID: 32349731
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
[TBL] [Abstract][Full Text] [Related]
10. [Ten years experience with the first approved biosimilar recombinant human growth hormone drug in normal clinical practice].
López-Siguero JP; Palla García M; Martínez Busto E; Rebollo FJ; Pombo M
An Pediatr (Engl Ed); 2018 Apr; 88(4):209-215. PubMed ID: 28668339
[TBL] [Abstract][Full Text] [Related]
11. 'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
Gaylis N; Both C; Lemke L; von Richter O; Yamauchi P
Adv Ther; 2024 May; 41(5):1795-1814. PubMed ID: 38514505
[TBL] [Abstract][Full Text] [Related]
12. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar growth hormone.
Saenger P
Indian J Pediatr; 2012 Jan; 79(1):92-8. PubMed ID: 22108957
[TBL] [Abstract][Full Text] [Related]
14. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults).
Höybye C; Beck-Peccoz P; Murray RD; Simsek S; Stalla G; Strasburger CJ; Urosevic D; Zouater H; Johannsson G
Pituitary; 2021 Aug; 24(4):622-629. PubMed ID: 33742320
[TBL] [Abstract][Full Text] [Related]
16. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
17. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.
Covic A; Abraham I
Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197
[TBL] [Abstract][Full Text] [Related]
18. Considerations related to comparative clinical studies for biosimilars.
Rathore AS; Stevenson JG; Chhabra H
Expert Opin Drug Saf; 2021 Mar; 20(3):265-274. PubMed ID: 33455482
[No Abstract] [Full Text] [Related]
19. What are biosimilars and are they important?
Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
[TBL] [Abstract][Full Text] [Related]
20. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
Aapro M; Krendyukov A; Schiestl M; Gascón P
BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
